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Abstract
B cell receptor sequences diversify through mutations introduced by purpose-built
cellular machinery. A recent paper has concluded that a “templated mutagenesis”
process is a major contributor to somatic hypermutation, and therefore immunoglob-
ulin diversification, in mice and humans. In this proposed process, mutations in
the immunoglobulin locus are introduced by copying short segments from other im-
munoglobulin genes. If true, this would overturn decades of research on B cell diver-
sification, and would require a complete re-write of computational methods to analyze
B cell data for these species.
In this paper, we re-evaluate the templated mutagenesis hypothesis. By applying
the original inferential method using potential donor templates absent from B cell
genomes, we obtain estimates of the methods’s false positive rates. We find false
positive rates of templated mutagenesis in murine and human immunoglobulin loci
that are similar to or even higher than the original rate inferences, and by considering
the bases used in substitution we find evidence that if templated mutagenesis occurs,
it is at a low rate. We also show that the statistically significant results in the original
paper can easily result from a slight misspecification of the null model.
Key points
• A recent study proposes a new process as the dominant mechanism of human/mouse SHM.
• We re-examine these results by estimating the false positive rates of their approach.
• We find no evidence that templated mutagenesis is a major contributor to SHM.
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Introduction
Our immune systems generate a highly diverse set of antibodies to protect us from pathogens. An
important part of this process is affinity maturation, which generates high-affinity antibodies for
antigens encountered by the immune system. Affinity maturation is the result of multiple rounds of
mutation and selection: mutations are introduced into the rearranged antibody gene by enzymatic
processes, and mutations leading to higher-affinity antibodies are selected.
Two major processes are believed to underlie the mutation processes in B cells: classical somatic
hypermutation (SHM) and gene conversion (GCV). Both processes depend on activation-induced
cytidine deaminase (AID) (1), which creates U:G lesions in the DNA by deaminating deoxycyti-
dine to deoxyuridine. In SHM, the lesion is resolved by recruiting error-prone repair machinery
which can introduce non-templated point mutations at and around the AID-induced lesion. In GCV,
the lesion is repaired using a homologous segment elsewhere in the genome as a donor template,
resulting in the homologous tract being copied into the rearranged antibody gene.
In a recent paper, Dale et al. (2) propose that new mutation process, called “templated muta-
genesis,” is also an important contributor to B cell receptor diversification in mice and humans.
In this process, an incompletely-understood mechanism uses the sequence of other germline genes
to guide the mutation process at a rearranged germline gene. One candidate mechanism for this
process is gene conversion. However, templated mutagenesis differs from previous descriptions of
gene conversion (in species such as chicken) in that it does not require long stretches of homology
between donor and recipient sequences. Indeed, Dale et al. find that templated mutagenesis “ex-
tends into the somatically mutated non-Ig sequences, LAIR1, gpt, and β -globin, despite the lack of
overt homology between these genes and the IgHV repertoire.” For this paper we will simply refer
to this newly-hypothesized process as templated mutagenesis.
Although much of the evidence presented by Dale et al. was in the form of statistically signif-
icant deviations from a simplified null model, the authors suggest that ∼50-65% of mutations in
IgH from a collection of human and murine data sets are consistent with templated mutagenesis. If
over half of mutations truly come from templated mutagenesis, B cell repertoire analysis methods
will need to be rebuilt. For example, to estimate the likelihood of a group of mutations that match
a template elsewhere in the Ig locus, one must incorporate the respective likelihoods that the group
occurred from classical SHM or from templated mutagenesis. Therefore, any method that relies on
estimating mutation probabilities would need to be updated. This includes all core methods for B
cell sequence analysis: germline annotation, lineage tree estimation, selection strength estimation,
and validation techniques such as repertoire simulation. In light of this dependence, accurate rate
estimates of templated mutagenesis are crucial.
In this paper, we show that data from human samples (3) and data from a transgenic mouse
model (4) analyzed by Dale et al. do not support a high rate of templated mutagenesis. We do so
by re-implementing the software described in Dale et al., called PolyMotifFinder, which identi-
fies potential templated mutagenesis events by comparing mutated sequences to a pool of potential
donor genes. Using this software, we run a control experiment absent from the original analysis: we
calculate the rate of templated mutagenesis using a donor set of simulated genes not present in the
organism from which the mutated sequences derived. In this way, we show that the PolyMotifFinder
strategy for detecting templated mutagenesis via microhomology has a false positive rate very close
to, and in some cases above, the reported positive rate. This yields an upper bound on the range
of the true templated mutagenesis rate; this range is often zero. We also describe how Dale et al.
conflate a non-trivial rate of templated mutagenesis with significance estimates for a simplified null
model. In addition, we argue that clustering of mutations is compatible with the classical Neuberger
model of SHM and thus evidence of such clustering is not prima facie evidence of templated muta-
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genesis. We conclude that more evidence is needed if templated mutagenesis should be accepted as
an important part of BCR diversification.
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Materials and methods
Because the original software in Dale et al. was not made available as part of the publication, nor
was it available upon personal request without a materials transfer agreement restricting its use, we
re-implemented the algorithms described in Dale et al. as open-source software in Python, a widely
available and free programming language.
The PolyMotifFinder algorithm relies on the creation of two matrices. Given a set of n mutated
sequences all deriving from the same germline sequence, the length of which is p, and a window
size k corresponding to the minimum allowable donor tract length for templated mutagenesis, we
create matrices M and S, each having n rows and p columns. Si j = 1 if (i) there is a mutation at
position j in sequence i and (ii) there exists a window of size k around position j in the ith sequence
that contains at least two mutations and is represented in the donor set. That is, Si j is an indicator of
position j in sequence i belonging to a pair of mutations consistent with templated mutagenesis. For
M, we take Mi j = 1 if (i) there is a mutation at position j in sequence i, (ii) there is at least one other
mutation in sequence i whose distance from j is k− 1 or less, and (iii) that mutation is not part of
a pair of mutations that was seen in one of the previous sequences. In other words, M identifies the
set of unique mutations within a length-k window from other mutations. In Dale et al., S is referred
to as the scoring matrix and M as the mutation matrix. The templated mutagenesis coverage is then
computed as ∑ni=1∑
p
j=1Mi jSi j/∑
n
i=1∑
p
j=1Mi j.
We note in passing that calculation of the templated mutagenesis coverage depends on the order
in which the sequences are processed. As an example, consider the very abbreviated case where the
germline sequence is AAA, the donor set is the single sequence CT (so that k= 2), and the mutated
sequences are ATT and CTT. If the sequences are processed as ATT followed by CTT, we will have
S=
(
0 0 0
1 1 0
)
, M =
(
0 1 1
1 0 0
)
Then ∑i, jMi jSi j = 1, ∑i, jMi j = 3, for a templated mutagenesis coverage of 1/3.
If the sequences are processed in the opposite order, CTT followed by ATT, we have
S=
(
1 1 0
0 0 0
)
, M =
(
1 1 1
0 0 0
)
Then ∑i, jMi jSi j = 2, ∑i, jMi j = 3, for a templated mutagenesis coverage of 2/3. Nevertheless, we
re-implemented this order-dependent procedure.
PyMotifFinder, our package including a re-implementation of PolyMotifFinder, is available on
GitHub (https://github.com/matsengrp/PyMotifFinder), and our analysis scripts are avail-
able at https://github.com/matsengrp/TemplatedMutagenesis-1. Our implementation takes
as input pairs of naive and mutated sequences along with a donor gene set, the set of potential
templates for templated mutagenesis. It then computes a templated mutagenesis coverage ac-
cording to the strategy defined above. Our implementation contains unit tests to verify the accu-
racy of the algorithm. The sequence data used in our analyses are available on Zenodo (https:
//doi.org/10.5281/zenodo.3572361). The complete analysis starting from preprocessed data,
including generating the figures and tables included in this article, can be reproduced by copy-
pasting a handful of commands into a provided Docker container (5) as described in the GitHub
repository. All preprocessing scripts are included with the data on Zenodo.
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Sequence data sets
We analyzed three sets of mutated sequences: one from human subjects, and two from a trans-
genic mouse model. The first set of sequences, described in (3), corresponds to antibodies to the
membrane-anchored Ebola virus glycoprotein trimer. They were collected from the peripheral B
cells of a convalescent donor who survived the 2014 Ebola Zaire outbreak, and will be referred to
as the anti-Ebola sequences. The sequences were downloaded from GenBank using the accession
numbers corresponding to the heavy-chain sequences (taken from the supplemental material of (3)),
and both the accession numbers and sequences used are available on Zenodo.
The second and third sets of mutated sequences come from a transgenic mouse model de-
scribed in (4) which was also investigated by Dale et al.. Briefly, these sequences come from
the B cells of mice that have been genetically engineered with a modified heavy-chain locus. One
chromosome, with the “productive” allele, contains the pre-rearranged V region of the 4-hydroxy-
3-nitrophenylacetyl (NP)-binding B1-8 antibody (VB1-8). The other chromosome, with the “pas-
senger” allele, contains a sequence consisting of a VB1-8 promoter and leader, followed by a stop
codon, followed by either the E. coli gpt gene or another copy of VB1-8. The sequences on both
alleles accumulate mutations by somatic hypermutation following the immunization of the mice
with NP-chicken gamma globulin. Since the sequences on the passenger allele cannot be expressed,
the SHM patterns on these sequences are unaffected by natural selection, making the system partic-
ularly useful for studying SHM. The analyses presented here use only the passenger gpt or VB1-8
sequences from this system. The sequences come from B cells collected from either the Peyer’s
patches or the spleens of vaccinated mice (six samples from each), and we included sequences taken
from both tissue types in our analysis. These sequences will be referred to as the gpt sequences and
the VB1-8 sequences, respectively.
The gpt and VB1-8 sequences were downloaded from the Sequence Read Archive (SRP061422).
pRESTO (6) was used to assemble the raw paired-end reads, filter reads to those with an average
quality score of at least 20, remove PhiX contamination, and filter to sequences that were seen at
least twice. The script used for this process is available with the data on Zenodo.
Donor gene sets
For each mutation tract, PolyMotifFinder looks for templated mutagenesis from a provided donor
gene set, which contains potential templated mutagenesis donors: if a mutation tract in a mature
sequence matches exactly to a region in the donor gene set, the mutation is explainable by templated
mutagenesis from that donor set. We prepared five donor gene sets: a set of human IGHV genes,
two sets of mouse IGHV genes, and two “mock” sets containing simulated genes homologous to the
E. coli gpt gene. Because these simulated gpt homologs are not present in mouse, we use them as
controls as described below. We refer to these sets as the human IGHV gene set, the mouse IMGT
IGHV gene set, the mouse 129S1 IGHV gene set, and the mock gpt gene sets.
The human IGHV donor set was used to obtain the PyMotifFinder (PyMF) rate estimate of tem-
plated mutagenesis in the anti-Ebola sequences. This set consists of human IGHV gene segments
downloaded from IMGT (http://www.imgt.org/vquest/refseqh.html) in September 2017.
The IMGT label for this set was “F+ORF+all P,” corresponding to all functional genes, all open
reading frames, and all pseudogene alleles, yielding 466 total segments. A file containing these
segments is available on Zenodo.
The mouse IMGT IGHV gene set was used to obtain the PyMF rate estimate of templated
mutagenesis in the VB1-8 and gpt sequences. This set consists of mouse IGHV gene segments
downloaded from IMGT (http://www.imgt.org/vquest/refseqh.html) in September 2017.
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The IMGT label for this set was “F+ORF+all P,” corresponding to all functional genes, all open
reading frames, and all pseudogene alleles, yielding 499 total segments. A file containing these
segments is available on Zenodo.
The mouse 129S1 IGHV donor set was used primarily to describe what the mutation spectrum
would look like under a templated mutagenesis model in the transgenic mouse system described
in (4). While these mice belonged to strain 129P2, the 129P2 heavy-chain locus has not been
sequenced; instead, we used the set of IGHV genes present in the closely related strain 129S1,
published in (7). We note that the gene set is incomplete, with only the 3’ half of the IGHV locus
sequenced. Since this gene set was used primarily to describe the likelihood of mutations in a
model of templated mutagenesis and not to get at the rate of templated mutagenesis, we decided
that a partial set of genes that match closely those found in in the actual system was an appropriate
choice. In particular, we believe it is better than the alternative of using the mouse IGHV genes
taken from IMGT, which include several times as many genes as are present the 129P2 genome.
The sequenced and annotated region of the 129S1 genome was downloaded from GenBank (https:
//www.ncbi.nlm.nih.gov/nuccore/126349412). The V gene segments were extracted using a
custom Python script available on Zenodo.
The two mock gpt donor sets were used to estimate the false positive rate of the PolyMotifFinder
strategy with the human IMGT donor set and the false positive rate of the PolyMotifFinder strategy
with the mouse IMGT donor set. For a mock donor set to give a good estimate of the false positive
rate of the PolyMF strategy, the mock set should have approximately the same homology structure
as the donor set used by PolyMF. We created one such set for the human IMGT IGHV donor set and
one for the mouse IMGT IGHV donor set. In each case, we aligned the sequences in the gene set
using MUSCLE version 3.8.31 (8) and inferred a phylogenetic tree on the sequences using FastTree
version 2.1.7 (9). We then used pyvolve (10) to simulate a new set of sequences from the estimated
phylogenetic tree. In each case, the gpt sequence was the root, and the sequences were simulated
according to a continuous-time Markov process along the estimated phylogeny. We used the GY94
codon model (11) with parameters α = .98, β = .65.
All of the donor sets are available on Zenodo, along with the scripts used to extract the IGHV
gene segments from the 129S1 genome, the scripts to align and create trees from the human IGHV
genes and gpt genes, and the script to create the two mock gpt donor sets.
Germline annotation and mutation calling
To use PyMF on the anti-Ebola, VB1-8, and gpt sequences, we needed to identify the mutations and
the naive sequences. For the anti-Ebola and VB1-8 sequences, germline sequences and mutations
were identified using partis version 0.13.0 (12) with default germline V, D, and J gene sets. These
sets comprise curated subsets of the germline genes in IMGT: excluded are genes that are biologi-
cally implausible (e.g. on the wrong chromosome, non-functional, lacking the conserved cysteine)
or otherwise considered inaccurate (13).
For the gpt sequences, partis was run using a modified set of germline genes. The reference
sequence for the passenger gpt gene (obtained via personal communication with Dr. Leng-Siew
Yeap) was
CTTTCTCTCCACAGGTGTCCACTCCCAGGTCCAACTGTAGTAGATGAGCGAAAAATACATCGTCACCTGGGACAT
GTTGCAGATCCATGCACGTAAACTCGCAAGCCGACTGATGCCTTCTGAACAATGGAAAGGCATTATTGCCGTAAG
CCGTGGCGGTCTGGTACCGGGTGCGTTACTGGCGCGTGAACTGGGTATTCGTCATGTCGATACCGTTTGTATTTC
CAGCTACGATCACGACAACCAGCGCGAGCTTAAAGTGCTGAAACGCGCAGAAGGCGATGGCGAAGGCTTCATCGT
TATTGATGACCTGGTGGATACCGGTGGTACTGCGGTTGCGATTCGTGAAATCTGCAGTGACGCGCCCACTCTCAC
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AGTCTCCTCAGGTGAGTCCTTACAACCTCTCTCTT
In the reference sequence, positions 44 through 351 correspond to the first 308 nucleotides of the gpt
gene and the remainder are linkers. To align and call mutations from the germline sequence, partis
requires a set of germline V, D, and J gene segments. For the V gene segment, we used the first 308
nucleotides of the gpt gene, i.e., the portion of the gpt gene inserted into the mouse germline. For
the D and J gene segments, we used arbitrary “fake” gene segments: AAAAAAAAAA for the D gene
segment and GGGGGGGGGG for the J gene segment. We appended these segments to the end of each
sequence so that each input sequence to partis ended with AAAAAAAAAAGGGGGGGGGG. When used
this way, partis aligns the gpt portion of the sequence to the portion of the gpt gene included in the
reference, aligns the added suffix to the fake D and J gene segments, and treats the linker region
following the end of the gpt gene as a VD insertion. We validated the results by checking that each
inferred “V” sequence length was correct, that the inferred mutation rate in the “V” gene region
was not too high, that the inferred VD insertion lengths were correct, and that the VD insertion
sequences corresponded to the linker portion of the naive gpt sequence (positions 352 through 410
in the sequence above). Therefore, all mutations identified by partis are located on the gpt portion of
the sequence with none in the linker sequence. This is the desired behavior for our analysis because
we are looking for regions of microhomology in the gpt sequence and we do not wish to analyze
mutations that occurred in the linkers.
Model for mutation probabilities due to templated mutagenesis
To investigate whether templated mutagenesis could explain the observed mutations, we constructed
a simple statistical model for templated mutagenesis. The model assumes a uniform probability
distribution over the possible templated mutagenesis donors, so that each donor is equally likely to
have provided the template for a given templated mutation event. For each mutated site we identified
the three possible mutations: the mutation that actually occurred and the two mutations that did not
occur. For each of the three mutations, we identified all ways of aligning a donor gene to a mutation-
containing region so that the two match in at least k bases around the mutation. We defined this set
as the set of potential templated mutagenesis donors, and we modeled mutation due to templated
mutagenesis as a uniform draw from this set of donors. In this model, the probability of seeing
the observed mutation from a templated mutagenesis event is the number of donors containing the
observed mutation divided by the total number of donors. That is,
P(observed mutation | templated mutation event) = nobs
nobs+ nunobs
[1]
where nobs is the number of donors matching the observed mutation and nunobs is the number of
donors matching one of the two possible unobserved mutations. We can compute these probabilities
for any donor gene set to evaluate how well it explains the observed pattern of mutations.
Upper bound on the rate of templated mutagenesis
Given a bound on the false positive rate of PyMF and an estimate by PyMF of the rate of templated
mutagenesis, we can compute an upper bound on the true rate of templated mutagenesis. To do
this, we use a simple mixture model in which we assume that mutations arise either by templated
mutagenesis or by classical SHM. We first define the following quantities, all of which take values
in [0,1]:
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1. The false positive rate, FPR, is the probability that PyMF classifies a mutation due to classical
SHM as explainable by templated mutagenesis.
2. The true positive rate, TPR, is the probability that PyMF classifies a mutation due to tem-
plated mutagenesis as explainable by templated mutagenesis.
3. The positive rate, PR, is the overall probability that PyMF classifies a mutation as explainable
by templated mutagenesis.
4. pshm is the true proportion of classical SHM events. Since a mutation can be due to either
SHM or templated mutagenesis but not both, 1− pshm is the true proportion of templated
mutagenesis events.
Then the overall probability that PyMF classifies a mutation as explainable by templated mutagen-
esis is
PR = pshm×FPR+(1− pshm)×TPR.
If we assume that TPR = 1 so that all true templated mutagenesis events are correctly classified by
PyMF as due to templated mutagenesis (i.e., PyMF has sensitivity 1) and that FPR ≥ b for some
lower bound b, we can rearrange the expression above to conclude that pshm ≥ 1−PR1−b . Equivalently,
the rate of templated mutagenesis would be at most 1− 1−PR1−b . If we do not specify a true positive
rate, the upper bound for the rate of templated mutagenesis becomes
1− TPR−PR
TPR−FPR, [2]
assuming that TPR> FPR. If TPR< FPR, we cannot obtain an upper bound. We apply [2] to obtain
upper bounds on the rate of templated mutagenesis in mice and humans.
Hypothesis testing and confidence intervals
The gpt sequences have a grouped structure: each mutated sequence comes from one of 12 tissue
samples from 6 different organisms, and so it is inappropriate to model them as independent and
identically distributed. Hypothesis testing and confidence interval construction for the gpt sequences
was therefore performed using a mixed effects model fit with the lme4 package (14) in R (15). For
each value of k (the minimum donor tract length) and each reference sequence, we modeled the
probability of a mutation given templated mutagenesis using a mixed model with a random effect
for tissue sample. Confidence intervals were plotted as the fitted value in the mixed model plus
or minus two standard errors. To test whether templating from the IGHV genes could explain the
observed mutations better than templating from the gpt genes, we computed the probability of each
mutation under the model of templated mutagenesis by IGHV genes and templated mutagenesis
by gpt genes. We then computed the difference between the probability of the mutation under the
IGHV templating model and the gpt templating model. Under the null hypothesis that the two
models are equally good at explaining the observed mutations, these differences should have mean
zero. As before, since the mutations have a grouped structure, we tested this null hypothesis using
a mixed model with a random effect for tissue sample.
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Results
PyMotifFinder identifies a high fraction of mutations as explainable by
templated mutagenesis
To verify that our re-implementation of PolyMotifFinder was comparable to the version presented
by Dale et al., we ran PyMF on the gpt and VB1-8 sequences described in (4) with the mouse IGHV
gene set, as well as the anti-Ebola sequences described in (3) with the human IGHV gene donor set.
We found slightly higher but comparable rates of mutations explainable by templated mutagenesis in
the gpt sequences: of the mutations within 8 nucleotides of each other, 60-75% had 8-mer templates
in the mouse V genes (Figure 1), consistent with the initial report. We found a higher rate of
mutations explainable by templated mutagenesis in the anti-Ebola and VB1-8 sequences: of the
mutations within 8 nucleotides of each other, 73% of the anti-Ebola sequences had 8-mer templates
in the human V genes and 75% of the VB1-8 sequences had 8-mer templates in the mouse V genes.
The discrepancy is likely due to differences in gene filtering, germline annotation, and mutation
calling between our respective pipelines. Indeed, when we perform stricter filtering to our donor
gene sets by removing open reading frame and pseudogene sequences, we obtain rates estimates of
42% for humans and 62% for mice, which are very close to the Dale et al. estimates. We discuss
this in detail in Section "Consistent results using filtered donor gene sets".
gpt sequences can be used to estimate the PolyMotifFinder false positive
rate
To investigate the false positive rate of the PolyMotifFinder strategy, we ran PyMF on the set of
somatically mutated gpt sequences described in the "Sequence data sets" section using a mock
donor set of simulated gpt homologs that are not present in B cells. Since mutations could not have
arisen from copying over templates from our mock set, any inference of templated mutagenesis
events identified by the method must be a false positive. For the rate of false positives provided
by the mock donor gene set to provide a good estimate of the true false positive rate, the mock
donor gene set should be constructed so that the probability that an SHM-induced mutation in a gpt
sequence matches a member of the mock donor gene set is close to the probability that an SHM-
induced mutation in a real antibody sequence matches one of the IGHV genes. For this to hold,
the distribution of molecular divergences among the genes in the mock donor set should match the
distribution of divergences among the real donor gene set.
Our mock donor gene sets were created to have these properties. To verify this, we estimated
phylogenies for the two mock donor gene sets and the two IMGT IGHV gene sets and computed
the divergences between the roots and the leaves in each. The divergence distribution in the mock
gpt set based on the mouse IMGT gene set resembled the divergence distribution in the mouse
IMGT gene set (mean divergence .48 and .48, respectively). The same holds with the mock gpt set
based on the human IMGT gene set and the human IMGT gene set (mean divergence .41 and .4,
respectively). For a more complete description of the divergences, five-number summaries of the
divergences in each of the four gene sets are given in Supplemental Table I.
Finally, we note that in the gpt system, we expect all of the mutations to be introduced by
SHM. Although Dale et al. analyze these sequences and suggest that templated mutagenesis could
be occurring, the lack of homology between the gpt gene and the V genes makes it a priori unlikely
that these mutations are introduced by templated mutagenesis. We address the potential contribution
from small micro-homologies (matches of fewer than 10 bases) between the gpt gene and the IGHV
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Figure 1: Red points represent the fraction of mutations in the gpt gene explainable by tem-
plates in the mock donor set of simulated gpt homologs, which are not present in the mouse
germline and are not available as templates for templated mutagenesis (i.e., the FPR). Blue
points represent the fraction of mutations in the gpt gene explainable by templates in the
mouse IMGT IGHV gene donor set, which are potentially present in the mouse germline
and available as templates. For each tract length and donor set, the filled circle and error
bar represents the overall estimate of the probability of a mutation being explainable by
templated mutagenesis plus or minus two standard errors. We see that the FPR of PyMF
is larger on average than the PyMF estimate of the fraction of mutations explainable by
templated mutagenesis. Points corresponding to samples from Peyer’s patches and spleen
are offset slightly to the left and right, respectively, to facilitate comparison and to avoid
overplotting. This analysis was performed once on data from six individual mice, with two
replicates per mouse corresponding to samples from Peyer’s patches and spleen, yielding
12 total samples.
genes due to chance sequence similarity in Section “Evidence that mutations in gpt sequences are
not due to templating from V genes”.
gpt analysis demonstrates that the MotifFinder methodology has a high
false positive rate
To estimate the false positive rate of PyMF with the human IMGT IGHV gene set and the false pos-
itive rate of PyMF with the mouse IMGT IGHV gene set, we ran the algorithm on the gpt sequences
with the corresponding mock gpt donor gene set. Since the donor set of simulated gpt homologs
is not present in the mouse, they cannot have been used as templated mutagenesis donors, and any
mutation PyMF identifies as explainable by templated mutagenesis from this set is a false positive.
We ran PyMF with minimum donor tract length ranging from 8 to 14, and we found false positive
rates that were on the same order as the PolyMF rates obtained when mutated sequences were run
against real donor sets. The absolute false positive rates were particularly high for minimum donor
tracts of 8 and 9 (Figure 1). The average false positive rate was 83% for a donor tract of 8, 50%
for donor tracts of size 9, and 25% for donor tracts of size 10. This rate falls dramatically as the
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Figure 2: Average probability of the observed mutations under a templated mutagenesis
model, either templating from gpt genes or templating from the set of 129S1 V genes.
Each point corresponds to one sample taken from either spleen or Peyer’s patches, so that
the average is computed over all sequences in a given sample. This analysis was performed
once on data from six individual mice, with two replicates per mouse corresponding to
samples from Peyer’s patches and spleen, yielding 12 total samples.
minimum donor tract size increases, dropping to 5% for donor tracts of size 14. This suggests that
the PolyMotifFinder strategy has a large false positive rate for small values of k, classifying more
than 50% of mutations as explainable by templated mutagenesis from genes that were not present
in the mouse when k = 8 or k = 9.
Evidence that mutations in gpt sequences are not due to templating
from V genes
One might explain the high false positive rate of PolyMotifFinder by saying that in spite of the
overall lack of homology between gpt genes and V genes, the mutations in the gpt sequence were
actually introduced by templating from very small homologous tracts in the mouse V genes. To
check this possibility, we ran PyMF on the gpt sequences with the mouse IMGT IGHV genes as
a donor set. We found that many of the mutations could be explained by templating from very
small homologous tracts in the mouse V genes, corresponding to the findings of Dale et al.. For
example, nearly 60% of the mutations had a template of size 8 in the V gene set and about 40% of
the mutations had a template of size 9. However, the percentage approaches zero as template size
increases, and for every template size the average proportion of mutations explainable by templating
from gpt sequences is higher than the average proportion of mutations explainable by templating
from V genes (Figure 1). In fact, the proportion of mutations explainable by templating from the
V genes is very close to zero for templating by tracts of size 11 or greater, while the proportion
explainable by templating from the mock gpt donor set remains non-neglibible.
We next formally evaluated the plausibility that the mutations in the gpt sequences were intro-
duced by templated mutagenesis from the IGHV genes present in the mouse. To do so, we computed
the probabilities of the gpt mutations via templated mutagenesis from 129S1 IGHV donor gene set
and the probabilities of the gpt mutations via templated mutagenesis from the mock donor set of
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simulated gpt homologs, using the uniform-across-donors probability model specified by Equation
[1] for both cases. These models encode our intuition that if the mutations really were templated
from a donor gene set, the observed mutation spectrum should be biased towards bases that are
represented more frequently in potential donors from that gene set. As an example, suppose that
we are considering one mutation in the gpt sequence from A to T. If all of the potential templated
mutagenesis donors in the V gene set would lead to a mutation from A to T and all of the templated
mutagenesis donors in the gpt gene set would lead to a mutation from A to C, the observed A to T
mutation is explained better by templating from the V genes than by templating from the gpt genes.
We can fit one model using donors from the mouse V genes and another model using donors from
the gpt genes and compare how well each model explains the data: if templated mutagenesis from
mouse V genes were really occurring, we would expect the V gene model to fit the data better than
the gpt model. If this is not true, it suggests that both the V gene and the gpt inferences are spurious,
as the gpt donor genes are not actually present in the mouse.
For each sample, we computed the average probability of the mutations in the gpt sequences
given templated mutagenesis from the mouse IGHV gene donor set and the gpt donor set for tract
sizes ranging from 8 to 14. We found that these numbers were comparable for the gpt donor set and
the mouse IGHV gene donor set, as shown in Figure 2. As described in the Methods section, we
used a mixed effects model to test for a difference in the expected probabilities of mutation due to
templating from the gpt donor set and the mouse IGHV gene donor set. The resulting p-values were:
p= .059, .054, .115, .202, .001, .213, and .249 for k= 8 through 14, respectively. This indicates that
the mutations in the gpt sequences do not tend to look any more like the mouse IGHV gene donor
set than they do like the gpt donor set. Because the gpt donor set was not present in the mouse,
we believe that it is unlikely that the mutations in the gpt sequences were introduced by templating
from the mouse IGHV genes.
To further investigate whether the mutations could have arisen due to templated mutagenesis
from the mouse V genes, we asked whether mutations that had a higher probability under the tem-
plated mutagenesis model were observed more frequently. For each mutation from germline base
b1, we computed the probability of mutation from b1 to any of the other three bases at that posi-
tion under the templated mutagenesis model. We then asked whether target bases that had a higher
probability under the templated mutagenesis model were observed more frequently.
We found that mutations with higher probabilities under the templated mutagenesis model were
not observed any more frequently than mutations with low probabilities under the model (Figure 3).
This finding held true both for the model of templated mutagenesis from gpt genes and from the
129S1 IGHV genes. To formally test whether mutations with high probabilities occurred more
frequently, we performed independent logistic regressions for each pair of germline and target base.
The response variable was an indicator of whether the observed mutation was the target base, and the
predictor variable was the probability of mutation to the target base under the templated mutagenesis
model. In each case, we found that the slope in the model was non-significant at the .05 level,
indicating that the templated mutagenesis model did not help to explain the observed pattern of
mutations. This analysis provides further evidence that the mutations in the gpt sequences did not
arise by templated mutagenesis from the IGHV genes present in the mouse.
Upper bounds on the rate of templated mutagenesis
We combined PyMF’s estimate of the rate of templated mutagenesis with our estimate of PyMF’s
false positive rate to obtain an approximate upper bound on the true rate of templated mutagenesis
in mice (using the VB1-8 sequences) and in humans (using the anti-Ebola sequences). Plugging in
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Figure 3: Each subplot displays whether a mutation was observed (on the y-axis) versus its proba-
bility under the templated mutagenesis model (on the x-axis). A y-value of one means the mutation
was observed, and a y-value of zero means the mutation was not observed. For each mutation, the
germline base is indicated by the row name, and the target base indicated by the column name. The
lines are linear smoothers. We do not observe any consistent and significant trend to these lines,
indicating that templated mutagenesis has not contributed to the observed sequence changes in the
gpt sequence data set. This analysis was performed once on data from six individual mice, with two
replicates per mouse corresponding to samples from Peyer’s patches and spleen, yielding 12 total
samples.
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PyMF’s estimates of the rate of templated mutagenesis in the VB1-8 sequences and our estimates
of PyMF’s false positive rates from the gpt sequences to Equation 2, we found upper bounds on
the rate of templated mutagenesis in this system ranging from 0 (in cases where our estimate of the
false positive rate exceeds the rate at which PyMF identified templated mutations) to .1, depending
on the value of k and the assumed true positive rate (Table I, top panel). The largest upper bounds
were obtained at k = 8. For the human anti-Ebola sequences, we found upper bounds on the rate of
templated mutagenesis ranging from 0 to .12, with the numbers again varying based on the value of
k and the assumed true positive rate. In this case, the largest upper bounds is obtained at the largest
value of k, k= 14, and in general the larger values of k correspond to larger upper bounds. However,
note that, since these estimates are upper bounds of the true rates in both humans and mice, they are
consistent with a rate of zero.
Mice:
k PyMF rate PyMF FPR UB (1) UB (.99) UB (.95) UB (.9)
8 0.79 0.83 0 0 0 0
9 0.54 0.5 0.08 0.08 0.09 0.1
10 0.28 0.25 0.05 0.05 0.05 0.05
11 0.15 0.14 0.01 0.01 0.01 0.02
12 0.11 0.09 0.01 0.01 0.01 0.02
13 0.07 0.07 0 0 0 0
14 0.06 0.05 0.01 0.01 0.01 0.01
Humans:
k PyMF rate PyMF FPR UB (1) UB (.99) UB (.95) UB (.9)
8 0.73 0.78 0 0 0 0
9 0.44 0.43 0.02 0.02 0.02 0.02
10 0.26 0.2 0.07 0.08 0.08 0.09
11 0.18 0.11 0.09 0.09 0.09 0.1
12 0.15 0.07 0.09 0.1 0.1 0.11
13 0.15 0.05 0.1 0.1 0.11 0.11
14 0.13 0.03 0.1 0.11 0.11 0.12
Table I: Upper bounds (UB) on the rate of templated mutagenesis in the VB1-8 (top) and
the anti-Ebola sequences (bottom) computed for a range of tract lengths k and sensitivities.
k denotes tract length, PyMF rate is the naive PyMF estimate of the rate of templated
mutagenesis, PyMF FPR is the PyMF false positive rate, UB denotes upper bound, and the
number in parentheses denotes the assumed sensitivity (true positive rate) of PyMF.
We caution against taking these numbers as definitive as we do not know the true positive
rate of PyMF, and they require that our estimate of the false positive rate of PyMF is a lower
bound. However, they attempt to correct the observed rates using false positive rate estimates, and
in particular show that templated mutagenesis does not occur at a high rate unless PyMF misses
many true templated mutagenesis events.
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Consistent results using the reverse complementary strand
We also tested whether templated mutagenesis could be occurring from the reverse complementary
strand. To this end, we repeated all the analyses with the reverse complements added to the donor
gene sets. The results are shown in Supplemental Figures 1 and 2 and Supplemental Table II, and
were qualitatively similar to those with the original gene sets. The rate estimates were slightly
higher because of the larger size of the donor sets (Supplemental Figure 1). The average proba-
bility of the observed mutations given templated mutagenesis from the gpt genes and their reverse
complements remained about the same as the average probability of the observed mutations given
templated mutagenesis from the IGHV genes and their reverse complements (Supplemental Figure
2). The upper bounds on the rate of templated mutagenesis also remained low when the reverse
complements were included in the donor gene sets (Supplemental Table II).
Consistent results using filtered donor gene sets
We obtained positive rate estimates of 73% for humans and 79% for mice (Table I) when apply-
ing the PolyMotifFinder strategy with k = 8 using our chosen donor gene sets and BCR sequence
datasets as discussed in the Materials and Methods section. In their analysis, Dale et al. estimate
this positive rate to range to be approximately 50− 65% when applying the same strategy to their
chosen donor gene sets and BCR sequence datasets. While they describe the five different BCR
sequence datasets used to obtain these estimates, two things remain unclear. First, it is not obvious
how they extracted the 50− 65% range from the data displayed in their Figure 5(I), which seems
to show positive rate estimates roughly ranging from ≈ 30% to ≈ 90% and whose rate estimates
seem to depend on the dataset in question. Secondly, they do not describe the exact donor gene
sets obtained from IMGT. The construction of the donor sets is crucial since the number of genes in
the donor set influence the positive rate estimates: adding more templates to the donor set can only
increase the number of PolyMotifFinder hits since there will be more chances to observe a match.
To address these discrepancies, we re-ran both of the VB1-8 and anti-Ebola analyses using a
more restricted donor gene set in each case. Specifically, we filtered out all open reading frame
(ORF) and pseudogene (P) sequence reads from the respective IMGT sets, which led to a 31.7%
decrease in potential donors for the VB1-8 sequences and a 44.9% decrease in potential donors
for the anti-Ebola sequences. We obtained positive rate estimates of 42% for humans and 62% for
mice for k = 8. Detailed tables of rate estimates using the filtered donor sets, analogous to Table
I, can be found in the main Github respository (https://git.io/Jfl6t). Between the collective
full and restricted analyses for mice and humans, our positive rate estimates range from 42−79%,
which contains the 50−65% range proposed by Dale et al.. More importantly, our estimates on the
upper bound of templated mutagenesis events remain highly similar between the full and restricted
analyses, demonstrating the robustness of our methodology to the particular choice of donor gene
set.
A small p-value for a simplified null model does not imply a non-trivial
effect size for the rate of templated mutagenesis
Finally, we point out that our estimates of templated mutagenesis occurring at a low rate are in fact
compatible with the large values of Stouffer’s Z and the correspondingly small p-values obtained
in Dale et al.. These authors compare the rate of templated mutagenesis to the rate obtained using
a simplified null model (called RandomCheck) in which, conditional on the locations of the muta-
tions, the mutation identity at each location is independent of the other locations and follows a fixed
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distribution taken from previous studies. This model is a simplification of the classical Neuberger
model of somatic hypermutation in many ways. In the Neuberger model, lesions introduced by
AID can be resolved by one of three pathways, each of which leads to a repair by a different set
of enzymes. The likelihood of each pathway being recruited to repair the lesion depends on nu-
cleotide context, and each pathway is assumed to have its own unique, context-dependent mutation
profile (16). The result is that the mutations are not independent and identically distributed condi-
tional on the germline base, in contrast with the assumption of RandomCheck, which was used to
compute p-values and Stouffer’s Z in Dale et al.. Aside from issues of independence, the overall
mutation profile taken from the literature is exceedingly unlikely to be exactly correct, and, given
enough samples, any consistent hypothesis testing framework will confidently identify even small
differences between the true mutation profile and the one drawn from the literature.
To demonstrate that even a slightly misspecified model can lead to extreme values of Stouffer’s
Z and highly significant p-values, we performed a small simulation study. We suppose that the
fraction of mutations explainable by templated mutagenesis in the “true” model is drawn from a
beta distribution with mean .518 and variance .048, shown as a dashed line in Figure 4. In the
null model, the fraction of mutations explainable by templated mutagenesis is drawn from a beta
distribution with mean .5 and variance .05, shown as a solid line in Figure 4. We simulate 2,000
values (corresponding to 2,000 gpt sequences analyzed) for the fraction of mutations explainable
by templated mutagenesis, construct Z-values from the hypothesis test that these values come from
the null distribution, and finally compute Stouffer’s Z from the collection of 2,000 Z values. We
performed this procedure 10,000 times, yielding a distribution of 10,000 Stouffer’s Z values.
In this simulation, the values of Stouffer’s Z were centered around 3.65 with a standard deviation
of .97. The corresponding p-values had a median value of 1.3× 10−4. 10% of the p-values were
smaller than 4.2× 10−7, and 90% were smaller than 7.9× 10−3. The full distributions of both the
p-values and Z statistics are shown in Figure 4. These numbers are comparable to those reported in
Dale et al., and they show that even a very small amount of misspecification in the null model could
lead to very small p-values in the hypothesis testing framework.
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Figure 4: Top: Densities of the distributions used in the simulations of Stouffer’s Z. Sam-
ples coming from the “true” distribution (dashed line) are tested against the hypothesis
that they come from the null distribution (solid line). Bottom: Distributions of Stouffer’s
Z statistics (left) and p-values (right) for the true and null distributions in the top panel
for 10,000 simulation trials. In each trial, the Stouffer’s Z value is aggregated over 2,000
independent tests, which is about the same as the number of trials aggregated by Dale et
al..
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Discussion
Species rely on a variety of pathways for secondary antibody diversification, and the reasons for
this variety remain an immunological puzzle. The current understanding is that chickens, rabbits,
and some other species use a combination of gene conversion and somatic hypermutation during
affinity maturation, while humans and mice use only somatic hypermutation. A recent paper by
Dale et al. suggests that humans and mice also use extensive templated mutagenesis to diversify their
repertoires, which may happen by a mechanism similar to gene conversion. This finding was based
on a novel method, PolyMotifFinder, for identifying templated mutagenesis via microhomology,
and in this article we studied its properties.
We were interested in the false positive rate of the PolyMotifFinder strategy and developed
a novel way of estimating this rate. We ran the algorithm on two sets of mutation observations,
derived from mouse and human respectively, using two corresponding sets of simulated donor genes
not present in the subject in question; any inferences of templated mutagenesis in this case must be
spurious. The homology structure of these “mock” donor genes mimicked that of the set of potential
templated mutagenesis donors present in the subject. Using this method, we found that although
the PolyMotifFinder strategy is quite sensitive to templated mutagenesis, it also has a false positive
rate exceeding 50% for the donor tract sizes considered in Dale et al.. We used our estimates of the
false positive rates of the PolyMotifFinder strategy along with the naive PolyMotifFinder estimates
of the rate of templated mutagenesis to obtain upper bounds on the true rate in mice and humans.
In each case, we obtain upper bounds ranging from zero to around 10%, although because these are
upper bounds, the true rate may also be zero.
Many of the results in Dale et al. were based on findings of a statistically significant deviation
from a null model instead of an estimate of the rate of templated mutagenesis. The results of the
PolyMotifFinder/RandomCheck strategy were presented in terms of a Stouffer’s Z score, which de-
scribes deviation from a simplified null hypothesis about the way the mutations arise. We showed
that the observed Stouffer’s Z values and p-values in Dale et al. are not proof of templated mutage-
nesis, but merely reflect the fact that the specified null model is incorrect, and given thousands of
samples we have enough power to detect even small departures from it.
The same considerations apply to the findings of linkage disequilibrium in the mutated se-
quences: a statistically significant amount of linkage disequilibrium does not imply templated mu-
tagenesis, and is in fact entirely consistent with the Neuberger model. In particular, if a mutation-
generating process satisfies
• mutation at one site implies a higher probability of mutation at nearby sites, and
• not every base has an equal probability of being chosen as the new base for mutation,
then sites that are close together will be in linkage disequilibrium, even though the mutations are
not introduced by templated mutagenesis. One of the potential pathways posited by the Neuberger
model to resolve AID lesions has exactly the properties described above. In that pathway, an ex-
onuclease strips out several nucleotides around the AID-induced lesion, and the resulting single-
stranded sequence is patched by Pol η , an error-prone polymerase. Thus, a mutation at one position
is likely to be accompanied by mutations at neighboring positions, since Pol η might have intro-
duced multiple errors in the same patch of nucleotides. In addition, we do not expect Pol η to
replace nucleotides uniformly at random, since we expect bias in the nucleotide misincorporation
rate (16). We accordingly expect this pathway to cause linkage disequilibrium between sites, par-
ticularly those that are close together. Therefore, the observed significant linkage disequilibrium is
not prima facie evidence of templated mutagenesis.
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Next, we describe several limitations of the analysis presented here to be considered when
interpreting the results. First of all, our bounds depend on our estimate of the false positive rate
being an underestimate of the true false positive rate. We have two main reasons for believing that
this is true, particularly for the human sequences. The first is that our mock donor sets of simulated
gpt homologs are slightly smaller than the corresponding IMGT donor gene sets. The mock gpt set
based on the mouse IMGT IGHV genes has 462 unique genes, compared with 499 in the mouse
IMGT IGHV gene set. The corresponding numbers for the mock gpt set based on the human IMGT
IGHV genes and the human IMGT IGHV genes are 404 and 466. The mock gene sets have slightly
smaller numbers of genes than the gene sets they were based on because of the simulation method:
not all of the branches in the inferred tree actually lead to a mutation in the simulations, and so
there are fewer unique genes than leaves in the tree. Our second reason for believing our estimate
of the false positive rate is conservative involves the correspondence between diversity in variable
regions and mutation hotspots: in real antibody sequences, mutations are more likely to occur in the
CDRs, and there is also more variability in the IGHV genes in the CDRs. This is not the case for
the gpt sequences: as demonstrated in (4), there are mutation hotspots in the gpt genes as well, but
these hotspots do not correspond to regions of higher variability in the mock gpt gene sets. Since
mutations are more likely to occur in regions with more templated mutagenesis templates in the
antibody gene sequences than in the gpt sequences, we believe that the false positive rate estimate
based on the gpt sequences is lower than the true false positive rate.
We emphasize that we have obtained bounds on, not estimates of, the rate of templated muta-
genesis, and that these bounds depend on assumptions about the sensitivity of PyMF and on our
estimate of the false positive rate being conservative. For humans, the quality of the bound also
depends on how well our estimate of the PyMF false positive rate translates from mice to humans.
We were only able to estimate the false positive rate of PyMF in the mouse because of the transgenic
system set up in (4), and that estimate translates to humans to the extent that the somatic hypermu-
tation processes of the two species coincide. We expect the processes to be similar enough that the
false positive rate is valid for both species, but any differences that do exist mean that the bounds
for mice are more reliable than those for humans.
It is still possible that templated mutagenesis occurs at a low rate. If so, characterizing its prop-
erties is important because, even if templated mutagenesis events occur infrequently, they could
increase the rate of certain mutation patterns immensely. This has important implications for esti-
mation procedures (phylogenetic estimation, germline annotation, etc) as well as translational ap-
plications such as rational vaccine design. Thus, we do not view our work as closing the book on
the interesting possibility that templated mutagenesis could play a role in B cell diversification.
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Supplementary Materials
Donor set Min. 1st Qu. Median Mean 3rd Qu. Max.
gpt mock from Human 0.18 0.30 0.38 0.41 0.50 0.83
IMGT Human 0.23 0.31 0.36 0.40 0.46 0.74
gpt mock from mouse 0.18 0.39 0.49 0.48 0.58 0.79
IMGT Mouse 0.21 0.38 0.50 0.48 0.57 0.74
Supplemental Table I: Five-number summaries of the set of divergences between genes and
root for four donor gene sets. The divergences for the gpt human mock set are similar to
the divergences for the IMGT human set, and the divergences for the gpt mouse mock set
are similar to the divergences for the IMGT mouse set.
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Supplemental Figure 1: Hollow triangles represent the fraction of mutations explainable
by templated mutagenesis in each sample, with upward-pointing triangles corresponding
to samples from Peyer’s patches and downward-pointing triangles corresponding to sam-
ples from the spleen. Reverse complements are included in each donor set. For each tract
length, the filled circle and error bar represents the overall estimate of the probability of a
mutation being explainable by templated mutagenesis plus or minus two standard errors.
Points corresponding to samples from Peyer’s patches and spleen are offset slightly to the
left and right, respectively, to facilitate comparison and to avoid overplotting. This anal-
ysis was performed once on data from six individual mice, with two replicates per mouse
corresponding to samples from Peyer’s patches and spleen, yielding 12 total samples.
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Supplemental Figure 2: Average probability of the observed mutations under a templated
mutagenesis model, using gpt genes and their reverse complements (red) as well as the set
of 129S1 V genes and their reverse complements (blue). Each point corresponds to one
sample taken from either spleen or Peyer’s patches. This analysis was performed once on
data from six individual mice, with two replicates per mouse corresponding to samples
from Peyer’s patches and spleen, yielding 12 total samples.
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Mice:
k PyPMF rate PyPMF FPR UB (1) UB (.99) UB (.95) UB (.9)
8 0.9 0.94 0 0 0 —
9 0.7 0.7 0.02 0.02 0.03 0.03
10 0.46 0.36 0.15 0.15 0.16 0.18
11 0.22 0.18 0.04 0.04 0.04 0.04
12 0.13 0.11 0.03 0.03 0.03 0.03
13 0.08 0.07 0.01 0.01 0.01 0.01
14 0.06 0.05 0.01 0.01 0.01 0.01
Humans:
k PyPMF rate PyPMF FPR UB (1) UB (.99) UB (.95) UB (.9)
8 0.88 0.91 0 0 0 —
9 0.6 0.65 0 0 0 0
10 0.34 0.29 0.07 0.07 0.08 0.08
11 0.22 0.14 0.09 0.09 0.1 0.1
12 0.16 0.08 0.09 0.09 0.1 0.1
13 0.15 0.05 0.1 0.1 0.11 0.11
14 0.14 0.03 0.1 0.11 0.11 0.12
Supplemental Table II: Upper bounds (UB) on the rate of templated mutagenesis in the
VB1-8 (top) and the anti-Ebola sequences (bottom) computed for a range of tract lengths
k and sensitivities when including reverse complements in the donor set. k denotes tract
length, PyPolyMF rate is the naive PyPolyMF estimate of the rate of templated mutagene-
sis, PyPolyMF FPR is the PyPolyMF false positive rate, UB denotes upper bound, and the
number in paretheses denotes the assumed sensitivity (true positive rate) of PyPolyMF.
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